5:21 PM
 | 
Feb 11, 2010
 |  BC Extra  |  Clinical News

Ereska data reexamined

Javelin Pharmaceuticals Inc. (NYSE-A:JAV) released a reexamination by a third party biostatistics company of top-line data from a Phase III trial of Ereska ketamine to treat acute post-operative pain following orthopedic surgery. The reexamination showed Ereska met the primary...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >